![Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, [...] | Comunicati stampa CataniaOggi - Vimarsana News](https://vimarsana.com/images/vimarsana-bigimage.jpg)
Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, [...] | Comunicati stampa CataniaOggi
19 aprile 2021 12:14 Fonte: Adnkronos #salute-e-benessere SYDNEY, April 19, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has entered into a worldwide exclusive licensing agreement and a master services agreement with Evotec SE (FRA: EVT), a leading European drug discovery and development company, for EVT801, a small-molecule, first-in-class oncology drug candidate. Kazia expects to launch a phase I clinical trial of EVT801 in CY2021. Key Points Kazia CEO, Dr James Garner, commented, "We a...
Source: cataniaoggi.it